GNLX

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 14.25 USD with a low forecast of 3.50 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Genelux Corp revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Genelux Corp. EPS for the last quarter amounts to -0.21 USD, decreased -27.59 % YoY.

Genelux Corp (GNLX) has 24 emplpoyees as of August 12 2025.

Today GNLX has the market capitalization of 123.90M USD.